Nice link and I have time for a quick response...
First, a little grounding...
Generic manufacturers complete on price, which is why costs throughout the value chain are critical (no, not supply chain, that is only one element of the value chain). In looking at Elite's costs controls over time, I have been impressed...and it is a credit to Nasrat's stewardship. I know there have been complaints about Nasrat discussing the Covid protocols, as if a boilerplate statement like safe harbor. Well, it is not and that degree of attention to detail is why investors should feel good about operational cost controls.
Relatedly, generic manufacturers have seen their p/s turn south, as they continue to compete across a broad spectrum of products, many of which involve well contested markets, with many in slow or no growth. So...
That Elite has its two major products in a market with high consumer demand and insufficient product availability should tell us that both increasing market share and pricing will be #1 on the agenda of Mr. Kirkov, who has the experience to pull it off. And, I could not help but note Kirkov holds a master's degree from MIT. Given the competitive nature to get into a graduate program there, that is not too shabby.
News 
Market Data 
Discover 
